Search Result

Isoforms Recommended:	Autotaxin

Results for "

autotaxin

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LPL Receptor (2) Phosphodiesterase (PDE) (35)
By Research Areas:	Cancer (18) Inflammation/Immunology (20) Metabolic Disease (1) Neurological Disease (2)

Inhibitors & Agonists

Recombinant Proteins

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135053

Autotaxin-IN-3

Phosphodiesterase (PDE) Inflammation/Immunology

Autotaxin-IN-3 is a Autotaxin(ATX) inhibitor with an IC₅₀ of 2.4 nM, compound 33, sourced from patent WO2018212534A1 .

Autotaxin-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-3 is a *Autotaxin(ATX)* inhibitor with an IC₅₀ of 2.4 nM, compound 33, sourced from patent WO2018212534A1 .

HY-150614

Autotaxin-IN-6	Phosphodiesterase (PDE) LPL Receptor	Cancer
Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC₅₀ value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer .

HY-135089

Autotaxin-IN-5	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-5 (compound 63), extracted from patent WO2018212534A1, is an *Autotaxin* inhibitor. Autotaxin-IN-5 has the potential to treat idiopathic pulmonary fibrosis .

HY-135088

Autotaxin-IN-4	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-4 (compound 51), extracted from patent WO2018212534A1, is an *Autotaxin* inhibitor. Autotaxin-IN-4 has the potential to treat idiopathic pulmonary fibrosis .

HY-123637

Autotaxin-IN-1	Phosphodiesterase (PDE)	Inflammation/Immunology
Autotaxin-IN-1 is a potent *autotaxin* inhibitor, which has favorable potency (IC₅₀=2.2 nM), PK properties, and a robust PK/PD relationship. Autotaxin-IN-1 is used in treatment of osteoarthritis pain .

HY-12812

Autotaxin modulator 1	Phosphodiesterase (PDE)	Neurological Disease Cancer
Autotaxin modulator 1 is an autotaxin (ATX) enzyme inhibitor, extracted from patent WO 2014018881 A1, Compound Example 12b. Autotaxin modulator 1 is expected to be useful for researching demyelination due to injury or disease, as well as for researching proliferative disorders such as cancer .

HY-158001

MHC00188

Phosphodiesterase (PDE) Others Cancer

MHC00188 is an allosteric inhibitor for Autotaxin (ATX) with an IC₅₀ of 2.53 μM .

MHC00188	Phosphodiesterase (PDE)	Others Cancer
MHC00188 is an allosteric inhibitor for Autotaxin (ATX) with an IC₅₀ of 2.53 μM .

HY-124772

BI-2545	Phosphodiesterase (PDE)	Inflammation/Immunology
BI-2545 is a potent autotaxin (ATX) inhibitor that significantly reduces LPA, with IC₅₀s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively .

HY-116100A

HA155

Phosphodiesterase (PDE) Inflammation/Immunology

HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC₅₀ of 5.7 nM .

HA155	Phosphodiesterase (PDE)	Inflammation/Immunology
HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC₅₀ of 5.7 nM .

HY-134954

Palmitoleoyl 3-carbacyclic phosphatidic acid	Others	Cancer
Palmitoleoyl 3-carbacyclic phosphatidic acid (3ccPA 16:1) is an intermediately potent inhibitor of autotaxin (ATX) with an IC₅₀ of 620 nM. Palmitoleoyl 3-carbacyclic phosphatidic acid can be used for melanoma research .

HY-116100

(E/Z)-HA155	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology Cancer
(E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor. (E/Z)-HA155 can be used for researching cancer, fibrotic diseases, inflammation, pain and angiogenesis .

HY-145344

ONO-8430506	Phosphodiesterase (PDE)	Cancer
ONO-8430506 is an orally bioavailable and potent autotaxin (ATX)/ENPP2 inhibitor with the IC₉₀ of 100 nM for ATX activity in mouse plasma .

HY-143419

ATX inhibitor 14	Phosphodiesterase (PDE)	Inflammation/Immunology
ATX inhibitor 14 (compound 4), a indole-based carbamate derivative, is a potent autotaxin (ATX) inhibitor with an IC₅₀ of 0.41 nM. ATX inhibitor 14 has the potential for fibrosis relevant diseases research .

HY-146123

ATX inhibitor 20

Phosphodiesterase (PDE) Cancer

ATX inhibitor 20 (compound 24) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 2.3 nM .

ATX inhibitor 20	Phosphodiesterase (PDE)	Cancer
ATX inhibitor 20 (compound 24) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 2.3 nM .

HY-143420

ATX inhibitor 15	Phosphodiesterase (PDE)	Inflammation/Immunology
ATX inhibitor 15 (compound 30), a indole-based carbamate derivative, is a potent autotaxin (ATX) inhibitor with an IC₅₀ of 2.17 nM. ATX inhibitor 15 inhibits in vivo ATX and the gene expression of pro-fibrotic factors. ATX inhibitor 15 has lung protection effects in Bleomycin challenged mice lung fibrosis model .

HY-143237

ATX inhibitor 11	Phosphodiesterase (PDE)	Others
ATX inhibitor 11 (compound 13c) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 2.7 nM. ATX inhibitor 11 can typically alleviate the severity of fibrosis tissues and effectively reduce the deposition of fibrotic biomarker α-SMA in mice fibrosis model. ATX inhibitor 11 can be used for lung fibrosis research .

HY-123522

PAT-048	Phosphodiesterase (PDE)	Inflammation/Immunology
PAT-048 is a potent, selective and orally active *autotaxin* inhibitor, inhibits IL-6 mRNA expression, but shows no effect on autotaxin protein and pulmonary lysophosphatidic acid (LPA) production in lung fibrosis model. PAT-048 shows an IC₅₀ and IC₉₀ of 20 nM and 200 nM for autotaxin in mouse plasma. PAT-048 reduces dermal fibrosis in vivo .

HY-103267A

S32826	Phosphodiesterase (PDE)	Inflammation/Immunology
S32826 is a potent *autotaxin* inhibitor, with an IC₅₀ of 8.8 nM. S32826 shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 inhibits LPA release from adipocytes .

HY-144743

ATX inhibitor 12	Phosphodiesterase (PDE)	Others
ATX inhibitor 12 (compound 20) is an orally active and potent ATX (autotaxin) inhibitor, with an IC₅₀ of 1.72 nM. ATX inhibitor 12 effectively alleviates lung structural damage with fewer fibrotic lesions at an oral dose of 60 mg/kg in C57Bl/6J mice. ATX inhibitor 12 can be uesd for idiopathic pulmonary fibrosis (IPF) research .

HY-19329

HA130

4 Publications Verification

Phosphodiesterase (PDE) Cancer

HA130 is a selective autotaxin (ATX) inhibitor with an IC₅₀ of 28 nM.

HA130 4 Publications Verification	Phosphodiesterase (PDE)	Cancer
HA130 is a selective autotaxin (ATX) inhibitor with an IC₅₀ of 28 nM.

HY-103267

S32826 disodium	Phosphodiesterase (PDE)	Inflammation/Immunology
S32826 disodium is a potent *autotaxin* inhibitor, with an IC₅₀ of 8.8 nM. S32826 disodium shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 disodium inhibits LPA release from adipocytes .

HY-142644

ATX inhibitor 7

Phosphodiesterase (PDE) Inflammation/Immunology

ATX inhibitor 7 is a autotaxin inhibitor and shows good oral exposure.
HY-145561

Cudetaxestat

BLD-0409
Phosphodiesterase (PDE) Inflammation/Immunology

Cudetaxestat (BLD-0409) is a potent and orally active autotaxin (ATX) inhibitor .
HY-157997

MHC02181

Phosphodiesterase (PDE) Cancer

MHC02181 is a potent inhibitor of Autotaxin (ATX), with IC₅₀ of 9.41 μM .

ATX inhibitor 7	Phosphodiesterase (PDE)	Inflammation/Immunology
ATX inhibitor 7 is a *autotaxin* inhibitor and shows good oral exposure.

Cudetaxestat BLD-0409	Phosphodiesterase (PDE)	Inflammation/Immunology
Cudetaxestat (BLD-0409) is a potent and orally active *autotaxin* (ATX) inhibitor .

MHC02181	Phosphodiesterase (PDE)	Cancer
MHC02181 is a potent inhibitor of *Autotaxin* (ATX), with IC₅₀ of 9.41 μM .

HY-101772

Ziritaxestat 5 Publications Verification GLPG1690	Phosphodiesterase (PDE)	Inflammation/Immunology
Ziritaxestat (GLPG1690) is a first-in-class autotaxin (ATX) inhibitor, with an IC₅₀ of 131 nM and a K_i of 15 nM .

HY-146122

ATX inhibitor 19

Phosphodiesterase (PDE) Cancer

ATX inhibitor 19 (compound 22) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 156 nM .
HY-146124

ATX inhibitor 21

Phosphodiesterase (PDE) Cancer

ATX inhibitor 21 (compound 8) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 3490 nM .
HY-143581

ATX inhibitor 8

Phosphodiesterase (PDE) Inflammation/Immunology

ATX inhibitor 8 is a Autotaxin (ATX) inhibitor extracted from patent WO2018212534A1 compound 96 .

ATX inhibitor 19	Phosphodiesterase (PDE)	Cancer
ATX inhibitor 19 (compound 22) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 156 nM .

ATX inhibitor 21	Phosphodiesterase (PDE)	Cancer
ATX inhibitor 21 (compound 8) is a potent ATX (autotaxin) inhibitor, with an IC₅₀ of 3490 nM .

ATX inhibitor 8	Phosphodiesterase (PDE)	Inflammation/Immunology
ATX inhibitor 8 is a Autotaxin (ATX) inhibitor extracted from patent WO2018212534A1 compound 96 .

HY-13344

PF-8380 5 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
PF-8380 is a potent *autotaxin* inhibitor with an IC₅₀ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

HY-13344A

PF-8380 hydrochloride 5 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology Cancer
PF-8380 hydrochloride is a potent *autotaxin* inhibitor with an IC₅₀ of 2.8 nM in isolated enzyme assay and 101 nM in human whole blood.

HY-149018

ATX inhibitor 22

Phosphodiesterase (PDE) Cancer

ATX inhibitor 22 is a novel inhibitor of ATX (autotaxin) with IC₅₀ of 218 nM but lost its inhibitory activity of LPAR1 .

ATX inhibitor 22	Phosphodiesterase (PDE)	Cancer
ATX inhibitor 22 is a novel inhibitor of ATX (autotaxin) with IC₅₀ of 218 nM but lost its inhibitory activity of LPAR1 .

HY-126233

PAT-347	Phosphodiesterase (PDE)	Metabolic Disease
PAT-347 is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood .

HY-103035

BIO-32546

Phosphodiesterase (PDE) Cancer

BIO-32546 (example 12b, S-isomer) is an autotaxin (ATX) modulator (IC₅₀: 1 nM), extracted from the patent US20170158687A1 .

BIO-32546	Phosphodiesterase (PDE)	Cancer
BIO-32546 (example 12b, S-isomer) is an autotaxin (ATX) modulator (IC₅₀: 1 nM), extracted from the patent US20170158687A1 .

HY-107781

PAT-505	Phosphodiesterase (PDE)	Inflammation/Immunology
PAT-505 is a potent, selective, noncompetitive and orally available *autotaxin* inhibitor, with an IC₅₀ of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma.

HY-120797

CRT0273750	LPL Receptor	Cancer
CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC₅₀ = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancer .

HY-133019

ATX inhibitor 5	Phosphodiesterase (PDE)	Inflammation/Immunology
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC₅₀ of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently .

HY-149716

MEY-003	Phosphodiesterase (PDE)	Cancer
MEY-003 is an Autotaxin(ATX) inhibitor with EC₅₀s of 460 nM and 1.09 μM for hATX-β and hATX-ɣ (analysis with LPC18:1). MEY-003 behaves as a non-competitive inhibitor with K_iof 432 nM. MEY-003 can be used for targeted ATX-related disease research .

HY-143582

ATX inhibitor 9	Others	Cancer
ATX inhibitor 9 is a potent inhibitor of ATX. ATX inhibitor 9 is a thickened heteroaryl derivatives compound. Autotaxin (ATX), also known as ENPP2, is a secreted enzyme that is highly expressed mainly in cancer cells, bronchial epithelial cells and alveolar macrophages in the lung. ATX inhibitor 9 has the potential for the research of cancer or fibrous degenerative disease (extracted from patent WO2021078227A1, compound 3) .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P70167

	ENPP-2 Protein, Human (HEK293, His) rHuEctonucleotide phosphodiesterase family member 2/ENPP-2, His ; ATX; ATXFLJ26803; ATX-X; autotaxin; autotaxin-t; EC 3.1.4.39; ectonucleotide pyrophosphatase/phosphodiesterase 2; E-NPP 2; ENPP2; LysoPLD; NPP2; PD-IALPHA; PDNP2; PDNP2NPP2	Human	HEK293
	The ENPP-2 protein catalyzes the hydrolysis of lysophospholipids (especially lysophosphatidylcholine) to produce the signaling molecule lysophosphatidic acid (LPA). It also acts on sphingosine phosphocholine to produce sphingosine 1-phosphate, which affects cell movement. ENPP-2 Protein, Human (HEK293, His) is the recombinant human-derived ENPP-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of ENPP-2 Protein, Human (HEK293, His) is 828 a.a., with molecular weight of 100-120 kDa.

HY-P75733

	ENPP-2 Protein, Mouse (HEK293, His) Ectonucleotide pyrophosphatase/phosphodiesterase family member 2; autotaxin; LysoPLD; Npps2; Pdnp2	Mouse	HEK293
	ENPP-2 Protein catalyzes the hydrolysis of lysophospholipids, particularly lysophosphatidylcholine, generating the signaling molecule lysophosphatidic acid (LPA). It also acts on sphingosylphosphorylcholine, producing sphingosine-1-phosphate, influencing cell motility. ENPP-2 is involved in angiogenesis, neurite outgrowth, and tumor cell motility, showing a preference for specific lysophospholipid isomers. It plays a role in platelet activation, contributing to LPA production and cleaving sn-1 lysophospholipids. ENPP-2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived ENPP-2 protein, expressed by HEK293 , with N-His, N-10*His labeled tag. The total length of ENPP-2 Protein, Mouse (HEK293, His) is 814 a.a., with molecular weight of ~100 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: